{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:33:36Z","timestamp":1791290016845,"version":"4.3.0"},"reference-count":251,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Science Center, Poland","award":["OPUS 5, 2013\/09\/B\/NZ3\/00003"],"award-info":[{"award-number":["OPUS 5, 2013\/09\/B\/NZ3\/00003"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.pharmthera.2016.01.009","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T21:10:45Z","timestamp":1453497045000},"page":"35-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"special_numbering":"C","title":["The role of glucuronidation in drug resistance"],"prefix":"10.1016","volume":"159","author":[{"given":"Zofia","family":"Mazerska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mr\u00f3z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Paw\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2016.01.009_bb0005","first-page":"21","article-title":"Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese","volume":"46","author":"Akaba","year":"1998","journal-title":"Biochem Mol Biol Int"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0010","first-page":"3541","article-title":"Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues","volume":"53","author":"Albin","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0015","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1349-7006.2006.00321.x","article-title":"Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer","volume":"97","author":"Araki","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.0013-9580.2004.57703.x","article-title":"Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy","volume":"45","author":"Aronica","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0025","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.addr.2011.11.008","article-title":"Cerebral expression of drug transporters in epilepsy","volume":"64","author":"Aronica","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0030","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3109\/00498259109039556","article-title":"Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion","volume":"21","author":"Atsumi","year":"1991","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00228-010-0899-x","article-title":"Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects","volume":"67","author":"Bae","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1476-4598-10-80","article-title":"Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells","volume":"10","author":"Basseville","year":"2011","journal-title":"Mol Cancer"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/153537020523000206","article-title":"Modulation of p-glycoprotein transport function at the blood\u2013brain barrier","volume":"230","author":"Bauer","year":"2005","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0050","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bcp.2010.04.034","article-title":"Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): mechanisms responsible for interindividual variation of UGT levels","volume":"80","author":"Bock","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0055","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.bcp.2012.07.009","article-title":"Human UDP-glucuronosyltransferases: feedback loops between substrates and ligands of their transcription factors","volume":"84","author":"Bock","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2014.04.009","article-title":"Homeostatic control of xeno- and endobiotics in the drug metabolizing enzyme system","volume":"90","author":"Bock","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0070","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0006-2952(99)00366-4","article-title":"Coordinate induction by antioxidants of UDP-glucuronosyltransferase UGT1A6 and the apical conjugate export pump MRP2 (multidrug resistance protein 2) in caco-2 cells","volume":"59","author":"Bock","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0075","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.metabol.2006.01.006","article-title":"N-glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler\u2013Najjar type II","volume":"55","author":"Borlak","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0080","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/92.16.1295","article-title":"A family of drug transporters, the MRPs","volume":"92","author":"Borst","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0085","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2004.01.140","volume":"22","author":"Bouch\u00e9","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpsychires.2006.10.002","article-title":"Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients","volume":"42","author":"Bozina","year":"2008","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S1092852913000436","article-title":"The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study","volume":"19","author":"Breitenstein","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0065-230X(08)60983-5","article-title":"Mechanisms of resistance to anticancer agents","volume":"7","author":"Brockman","year":"1963","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0105","first-page":"46","article-title":"Genomics of schizophrenia and pharmacogenomics of antipsychotic drugs","volume":"3","author":"Cacabelos","year":"2013","journal-title":"O J Psych"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0110","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1158\/1078-0432.1226.11.3","article-title":"UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal patients treated with capecitabine\/irinotecan","volume":"11","author":"Carlini","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0115","doi-asserted-by":"crossref","first-page":"33580","DOI":"10.1074\/jbc.273.50.33580","article-title":"Characterization of the Ah receptor-associated protein, ARA9","volume":"273","author":"Carver","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0120","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0014-5793(00)01596-9","article-title":"Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver","volume":"474","author":"Cattori","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0125","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.1007\/s13277-015-3253-1","article-title":"Differential expression of the UGT1A family of genes in stomach cancer tissues","volume":"36","author":"Cengiz","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00126334-200308150-00001","article-title":"The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro","volume":"33","author":"Chandler","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0135","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0014-5793(03)01085-8","article-title":"Multidrug resistance ABC transporters","volume":"555","author":"Chang","year":"2003","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0140","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00228-014-1690-1","article-title":"Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China","volume":"70","author":"Chang","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0145","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/jpet.113.212258","article-title":"Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies","volume":"349","author":"Chau","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0150","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.molcel.2003.08.004","article-title":"A tweezers-like motion of ATP binding cassette dimer in an ABC transport cycle","volume":"12","author":"Chen","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/pgs.13.190","article-title":"Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics","volume":"15","author":"Chen","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0160","doi-asserted-by":"crossref","first-page":"19143","DOI":"10.1073\/pnas.1319123110","article-title":"Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11)","volume":"110","author":"Chen","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0170","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jpba.2012.11.022","article-title":"Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC\/MS\/MS","volume":"75","author":"Cho","year":"2013","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0165","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/FPC.0b013e3283544085","article-title":"The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers","volume":"22","author":"Cho","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-5-30","article-title":"ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal","volume":"5","author":"Choi","year":"2005","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0180","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1021\/jm00172a028","article-title":"8-Substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity","volume":"33","author":"Cho\u0142ody","year":"1990","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0185","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1021\/jm00080a026","article-title":"Chromophore modified antineoplastic imidazoacridiones. Synthesis and activity against murine leukemias","volume":"35","author":"Cho\u0142ody","year":"1992","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0190","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0022-3565(24)36601-7","article-title":"Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats","volume":"281","author":"Chu","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0195","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0022-3565(24)38014-0","article-title":"Active efflux of CPT-11 and its metabolites in human KB-derived cell lines","volume":"288","author":"Chu","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0200","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.2549","article-title":"Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [14C]-panobinostat","volume":"27","author":"Clive","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0205","first-page":"73","article-title":"The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)","volume":"26","author":"Coffman","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0210","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0215","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/00498254.2011.618954","article-title":"Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues","volume":"42","author":"Court","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0220","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0378-4274(01)00305-8","article-title":"Characterisation of glucuronidation and transport in V79 cells co-expressing UGT1A1 and MRP1","volume":"120","author":"Cuff","year":"2001","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0225","doi-asserted-by":"crossref","first-page":"9626","DOI":"10.1074\/jbc.M004968200","article-title":"Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6","volume":"276","author":"Cui","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0230","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0006-2952(01)00812-7","article-title":"Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation","volume":"63","author":"Cummings","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0240","first-page":"8443","article-title":"Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives","volume":"63","author":"Cummings","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0235","first-page":"2189","article-title":"Glucuronidation of SN-38 and NU\/ICRF 505 in human colon cancer and adjacent normal colon","volume":"26","author":"Cummings","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0245","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00685636","article-title":"Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography","volume":"37","author":"Cummings","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0250","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bcp.2003.07.019","article-title":"Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins","volume":"67","author":"Cummings","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0255","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.6-suppl_4-17","article-title":"Optimizing the use of irinotecan in colorectal cancer","volume":"6","author":"Cunningham","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0260","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2141.2011.08591.x","article-title":"Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-\u03baB and Bim","volume":"153","author":"Dai","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0265","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bcp.2010.09.008","article-title":"UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate","volume":"8","author":"de Almagro","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0270","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.canlet.2005.04.040","article-title":"Role of pharmacogenetics in irinotecan therapy","volume":"234","author":"de Jong","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0275","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.trre.2007.09.002","article-title":"Pharmacogenetics in solid organ transplantation: current status and future directions","volume":"22","author":"de Jonge","year":"2008","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0280","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.108.026146","article-title":"Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2","volume":"37","author":"de Waart","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0285","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1152\/physrev.00035.2005","article-title":"Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins","volume":"86","author":"Deeley","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047696","article-title":"Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells","volume":"7","author":"Dellinger","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0295","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1161\/HYPERTENSIONAHA.109.129742","article-title":"Unveiling the role of multidrug resistance proteins in hypertension","volume":"54","author":"Delou","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0300","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1046\/j.1528-1157.2001.12301.x","article-title":"Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy","volume":"42","author":"Dombrowski","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0305","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","article-title":"Treatment of postmenopausal osteoporosis","volume":"338","author":"Eastell","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0310","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2005.02.005","article-title":"Pharmacogenetics for individualized cancer chemotherapy","volume":"107","author":"Efferth","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0315","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/j.1476-5381.2011.01672.x","article-title":"Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells","volume":"165","author":"Fahrmayr","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0320","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1124\/dmd.112.045401","article-title":"Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10","volume":"40","author":"Fedejko-Kap","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0325","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/carcin\/17.11.2279","article-title":"Estrogens and breast cancer","volume":"17","author":"Feigelson","year":"1996","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0330","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.transproceed.2009.03.024","article-title":"Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs","volume":"41","author":"Felipe","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0335","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2789","article-title":"ABC transporters in cancer: more than just drug efflux pumps","volume":"10","author":"Fletcher","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0340","first-page":"984","article-title":"Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells","volume":"56","author":"Franklin","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0345","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/0049825021000017957","article-title":"Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization","volume":"33","author":"Fujino","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0350","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/mol.62.3.608","article-title":"Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)","volume":"62","author":"Gagn\u00e9","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0355","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/FPC.0b013e32801112b5","article-title":"Hepatocyte nuclear factor1 transcription factors are essential for the UDP-glucuronosyltransferase 1A9 promoter response to hepatocyte nuclear factor 4alpha","volume":"17","author":"Gardner-Stephen","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0360","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cca.2011.12.003","article-title":"The association of the UGT1A8, SLCO1B3 and ABCC2\/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals","volume":"413","author":"Geng","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0365","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0002-9440(10)62572-2","article-title":"Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers","volume":"160","author":"Gestl","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0370","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.32.3.314","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia)","volume":"32","author":"Ghosal","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0375","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/epi.12318","article-title":"Expression and functional relevance of UGT1A4 in a cohort of human drug-resistant epileptic brains","volume":"54","author":"Ghosh","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0380","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-009-0783-8","article-title":"Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure\u2014an impact similar to male gender or smoking in schizophrenic patients","volume":"66","author":"Ghotbi","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0385","first-page":"185","article-title":"UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry","volume":"13","author":"Giuliani","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0390","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0395","doi-asserted-by":"crossref","first-page":"36107","DOI":"10.1074\/jbc.M305565200","article-title":"Cloning and characterization of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 gene promoters: differential regulation through an iterior-like region","volume":"278","author":"Gregory","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0400","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/01.fpc.0000215068.06471.35","article-title":"The caudal-related homeodomain protein Cdx2 and hepatocyte nuclear factor 1alpha cooperatively regulate the UDP-glucuronosyltransferase 2B7 gene promoter","volume":"16","author":"Gregory","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0405","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1124\/mol.65.4.953","article-title":"Coordinate regulation of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 genes by hepatocyte nuclear factor 1alpha and the caudal-related homeodomain protein 2","volume":"65","author":"Gregory","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0410","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/03602530903210682","article-title":"UGT genomic diversity: beyond gene duplication","volume":"42","author":"Guillemette","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0415","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1124\/dmd.30.4.457","volume":"30","author":"Guo","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0420","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/jac\/dkr304","article-title":"Long-term effect of efavirenz autoinduction on plasma\/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients","volume":"66","author":"Habtewold","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0425","first-page":"1829","article-title":"Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit","volume":"48","author":"Hande","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0430","first-page":"379","article-title":"Pharmacokinetics of high-dose etoposide (VP-16-213) administrated to cancer patients","volume":"44","author":"Hande","year":"1984","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0435","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1742-7843.2011.00790.x","article-title":"Expression and inducibility of UDP-glucuronosyltransferase 1As in MCF-7 human breast carcinoma cells","volume":"110","author":"Hanioka","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0440","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/00498250110057341","article-title":"Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin","volume":"31","author":"Hanioka","year":"2001","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0445","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/cncr.11055","article-title":"Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma","volume":"97","author":"Harris","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0450","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1681\/ASN.2005090966","article-title":"Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide","volume":"18","author":"Hasegawa","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0455","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1039\/C5TX00100E","article-title":"Amelioration of mercury nephrotoxicity after pharmacological manipulation of organic anion transporter 1 (Oat1) and multidrug resistance-associated protein 2 (Mrp2) with furosemide","volume":"4","author":"Hazelhoff","year":"2015","journal-title":"Toxicol Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0460","doi-asserted-by":"crossref","first-page":"15181","DOI":"10.1074\/jbc.274.21.15181","article-title":"Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3)","volume":"274","author":"Hirohashi","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0465","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/j.1476-5381.2011.01665.x","article-title":"Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor","volume":"165","author":"Hoffart","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0470","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0475","first-page":"4385","article-title":"DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues","volume":"49","author":"Hsiang","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0480","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1124\/mol.109.057380","article-title":"Estrogen receptor alpha, fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17beta-estradiol in MCF-7 cells","volume":"76","author":"Hu","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0485","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1124\/dmd.110.035436","article-title":"Forkhead box protein A1 regulates UDP glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells","volume":"38","author":"Hu","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0490","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1124\/mol.114.091603","article-title":"Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway","volume":"85","author":"Hu","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0495","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/FPC.0b013e3283489ce2","article-title":"Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose","volume":"21","author":"Ieiri","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0500","first-page":"686","article-title":"Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7","volume":"29","author":"Innocenti","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0505","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1200\/JCO.2005.05.2464","article-title":"Irinogenetics: what is the right star?","volume":"24","author":"Innocenti","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0510","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ejca.2009.12.005","article-title":"Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours","volume":"46","author":"Isambert","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0515","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1248\/bpb.b12-00568","article-title":"Inhibition of morphine glucuronidation in the liver microsomes of rats and humans by monoterpenoid alcohols","volume":"35","author":"Ishii","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0520","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.tpj.6500072","article-title":"UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity","volume":"2","author":"Iyer","year":"2002","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0525","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1172\/JCI915","article-title":"Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes","volume":"101","author":"Iyer","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0530","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkm353","article-title":"Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes","volume":"60","author":"Janneh","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0535","first-page":"988","article-title":"Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump","volume":"56","author":"Jedlitschky","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0540","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3109\/00498254.2014.942810","article-title":"Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3","volume":"45","author":"Jeong","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0545","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00018-003-3336-9","article-title":"The ABC transporter structure and mechanism: perspectives on recent research","volume":"61","author":"Jones","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0550","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00713399","article-title":"\u201cStudies on the estrogen receptor in breast cancer\u201d \u2014 20years as a target for the treatment and prevention of cancer","volume":"36","author":"Jordan","year":"1995","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0555","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00228-010-0850-1","article-title":"The role of CYP2D6 and ABCB1 pharmacogenetics in drug-na\u00efve patients with first-episode schizophrenia treated with risperidone","volume":"66","author":"Jovanovi\u0107","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0560","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1517\/17425255.2015.1028356","article-title":"Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism","volume":"11","author":"Joyce","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0565","first-page":"885","article-title":"Expression of ABC transporters in human hepatocyte carcinoma cells with cross-resistance to epirubicin and mitoxantrone","volume":"26","author":"Kamiyama","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0570","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/FPC.0b013e32833e1b37","article-title":"A pharmacogenetic study of vorinostat glucuronidation","volume":"20","author":"Kang","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0575","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1126\/science.6137059","article-title":"Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines","volume":"221","author":"Kartner","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0580","first-page":"112","article-title":"Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells","volume":"44","author":"Katzenellenbogen","year":"1984","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0585","first-page":"3451","article-title":"Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies","volume":"6","author":"Kehrer","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0590","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1124\/dmd.30.6.694","article-title":"Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance","volume":"30","author":"Kemp","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0595","first-page":"787","article-title":"Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2","volume":"378","author":"Keppler","year":"2000","journal-title":"Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0600","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bcp.2008.04.014","article-title":"In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway","volume":"76","author":"Kerdpin","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0605","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1172\/JCI1269","article-title":"The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors","volume":"101","author":"Kim","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb9471","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/03602530903208561","article-title":"Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators","volume":"42","author":"Knights","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0610","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJM199908123410707","article-title":"Drug treatment of lipid disorders","volume":"341","author":"Knopp","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0615","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejps.2013.03.001","article-title":"Effect of UDP-glucuronosyltransferase 1A8 polymorphism on raloxifene glucuronidation","volume":"49","author":"Kokawa","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0620","doi-asserted-by":"crossref","first-page":"23161","DOI":"10.1074\/jbc.M001448200","article-title":"Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide","volume":"275","author":"K\u00f6nig","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0625","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/ars.2008.2095","article-title":"Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities","volume":"11","author":"Kou","year":"2009","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0630","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eplepsyres.2005.11.011","article-title":"Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis","volume":"68","author":"Kubota","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0635","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.2","article-title":"Glucuronidation of drugs in humanized UDP-glucuronosyltransferase 1 mice: similarity with glucuronidation in human liver microsomes","volume":"1","author":"Kutsuno","year":"2013","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0640","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/0091270009338482","article-title":"Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB\/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation","volume":"49","author":"Kwara","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0645","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1097\/QAD.0b013e3283319908","article-title":"CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients","volume":"23","author":"Kwara","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0650","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1470320312466124","article-title":"MDR-1 C3435T polymorphism may affect blood pressure in resistant hypertensive patients independently of its effects on aldosterone release","volume":"15","author":"Lacchini","year":"2014","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0655","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1345\/aph.1K628","article-title":"Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?","volume":"42","author":"Lam","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0660","first-page":"30","article-title":"The global role of irinotecan in the treatment of lung cancer: 2003 update","volume":"17","author":"Langer","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0665","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jnen\/63.10.1038","article-title":"Altered P-glycoprotein expression in AIDS patients with HIV encephalitis","volume":"63","author":"Langford","year":"2004","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0670","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00007691-200402000-00010","article-title":"Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy","volume":"26","author":"Lazarowski","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0675","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","article-title":"Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense","volume":"204","author":"Leslie","year":"2005","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0680","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.bbrc.2006.02.094","article-title":"Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate","volume":"342","author":"Li","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0685","first-page":"2175","article-title":"Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment","volume":"49","author":"Lien","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0690","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00280-004-0926-7","article-title":"Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen","volume":"55","author":"Lim","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0695","first-page":"261","article-title":"Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure","volume":"58","author":"Lippert","year":"2008","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0705","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.taap.2012.08.032","article-title":"Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin","volume":"265","author":"Liu","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0710","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jpba.2010.12.004","article-title":"Sensitive and robust UPLC-MS\/MS method to determine the gender-dependent pharmacokinetics in rats of emodin and its glucuronide","volume":"54","author":"Liu","year":"2011","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0715","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1098\/rstb.2008.0125","article-title":"Structure and mechanism of ATP-binding cassette transporters","volume":"364","author":"Locher","year":"2009","journal-title":"Philos Trans R Soc B"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0720","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood\u2013brain barrier active efflux Transporters: ATP-binding cassette gene family","volume":"2","author":"L\u00f6scher","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0725","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pneurobio.2005.04.006","article-title":"Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases","volume":"76","author":"L\u00f6scher","year":"2005","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0730","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrn1728","article-title":"Drug resistance in brain diseases and the role of drug efflux transporters","volume":"6","author":"L\u00f6scher","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0735","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/BF00178720","article-title":"Morphine-6-O-beta-d-glucuronide but not morphine-3-O-beta-d-glucuronide binds to mu-, delta- and kappa- specific opioid binding sites in cerebral membranes","volume":"354","author":"L\u00f6ser","year":"1996","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0740","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FTD.0b013e31826517c6","article-title":"Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy","volume":"34","author":"Lovri\u0107","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0745","doi-asserted-by":"crossref","DOI":"10.1145\/2818302","article-title":"Drug-metabolizing activity, protein and gene expression of UDP-glucuronosyltransferases are significantly altered in hepatocellular carcinoma patients","volume":"10","author":"Lu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0750","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.neuropharm.2010.01.007","article-title":"Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy","volume":"58","author":"Luna-Tort\u00f3s","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0755","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.fpc.0000173483.13689.56","article-title":"Nomenclature update for the mammalian UDP-glucuronosyltransferase (UGT) gene superfamily","volume":"15","author":"Mackenzie","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0760","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1124\/mol.110.069336","article-title":"The novel UDP glucuronosyltransferase 3A2: cloning, catalytic properties, and tissue distribution","volume":"79","author":"Mackenzie","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0765","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1124\/dmd.114.062877","article-title":"Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues","volume":"43","author":"Margaillan","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0770","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","volume":"8","author":"Mathijssen","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0775","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ctrv.2008.03.002","article-title":"Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer","volume":"34","author":"Meijerman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0780","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.curtheres.2014.05.002","article-title":"Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers","volume":"76","author":"Metzger","year":"2014","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0785","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/clpt.2012.34","article-title":"Compartment-specific gene regulation of the CAR inducer efavirenz in vivo","volume":"92","author":"Meyer zu Schwabedissen","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0790","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/pr.111.005553","article-title":"The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition","volume":"64","author":"Michaud","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0795","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cca.2008.09.020","article-title":"Telmisartan pharmacokinetics in Japanese renal transplant recipients","volume":"399","author":"Miura","year":"2009","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0800","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1124\/dmd.104.002576","article-title":"UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation","volume":"33","author":"Mori","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0810","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/03602530600739835","article-title":"Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan","volume":"38","author":"Nagar","year":"2006","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0820","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bcp.2013.05.008","article-title":"Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia","volume":"86","author":"Niemira","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0825","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJM198503143121106","article-title":"Etoposide (VP-16-213): current status of an active anticancer drug","volume":"312","author":"O'Dwyer","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0830","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bcp.2013.11.001","article-title":"Epigenetic regulation of tissue-specific expression of human UDP-glucuronosyltransferase (UGT) 1A10","volume":"87","author":"Oda","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0835","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.dmpk.2014.12.001","article-title":"A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development","volume":"30","author":"Oda","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0840","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.bcp.2006.01.004","article-title":"Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4","volume":"71","author":"Ogura","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0845","first-page":"2893","article-title":"UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers","volume":"24","author":"Oguri","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0850","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/clpt.2009.171","article-title":"Quantification of T-cell proliferation for individualizing immunosuppressive therapy for transplantation patients","volume":"87","author":"Ohdan","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0855","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/dmd.108.023598","article-title":"Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction","volume":"37","author":"Ohno","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0860","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/jn\/122.suppl_3.615","article-title":"Enhancement of biological activity by conjugation reactions","volume":"122","author":"Olson","year":"1992","journal-title":"J Nutr"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0865","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002512-199915050-00006","article-title":"Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer","volume":"15","author":"Omrod","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0870","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1124\/jpet.106.104018","article-title":"Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats","volume":"318","author":"Oswald","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0875","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3389\/fncel.2014.00349","article-title":"The UDP-glucuronosyltransferases of the blood\u2013brain barrier: their role in drug metabolism and detoxication","volume":"8","author":"Ouzzine","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0880","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.maturitas.2011.11.010","article-title":"EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis","volume":"71","author":"Palacios","year":"2012","journal-title":"Maturitas"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0885","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/653427","article-title":"Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency","volume":"51","author":"Park","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0890","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-3565(25)20832-1","article-title":"Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite","volume":"251","author":"Paul","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0895","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/dmd.112.047811","article-title":"Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use","volume":"41","author":"Paw\u0142owska","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0900","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1211\/jpp.59.7.0006","article-title":"Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells","volume":"59","author":"Perloff","year":"2007","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0905","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/dmd.104.001651","article-title":"Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism","volume":"33","author":"Picard","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0910","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.103.049858","article-title":"Multidrug resistance protein MRP2 contributes to blood\u2013brain barrier function and restricts antiepileptic drug activity","volume":"306","author":"Potschka","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0915","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/dmd.30.5.505","article-title":"Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0920","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.12.180","article-title":"Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy","volume":"14","author":"Puranik","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0925","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/03602530903209049","article-title":"The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families","volume":"42","author":"Radominska-Pandya","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0930","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-4598-9-46","article-title":"Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation","volume":"9","author":"Raynal","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0935","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0940","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2009.181","article-title":"UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo","volume":"87","author":"Riedmaier","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0945","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1677\/erc.1.00776","article-title":"Mechanisms of tamoxifen resistance","volume":"11","author":"Ring","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0950","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/glia.20725","article-title":"Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection","volume":"56","author":"Ronaldson","year":"2008","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0955","first-page":"5857","article-title":"Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage","volume":"44","author":"Ross","year":"1984","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0960","series-title":"Resistance to Targeted ABC Transporters in Cancer","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-09801-2_2","article-title":"Clinical relevance of multidrug-resistance-proteins (MRPs) for anticancer drug resistance and prognosis","author":"Roundhill","year":"2015"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0965","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","article-title":"The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification","volume":"45","author":"Rowland","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0970","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1006\/taap.1997.8322","article-title":"Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: a novel role for phase-II-mediated bioactivation in the hepatocarcinogenicity of the parent aglycones?","volume":"147","author":"Sallustio","year":"1997","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0975","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1349-7006.2011.02030.x","article-title":"Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and\/or UGT1A1*6 polymorphisms","volume":"102","author":"Satoh","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1711","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0980","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1021\/acs.molpharmaceut.5b00474","article-title":"Statin lactonization by uridine 5\u2032-diphospho-glucuronosyltransferases (UGTs)","volume":"12","author":"Schirris","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0985","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1528-1167.2005.54904.x","article-title":"Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms","volume":"46","author":"Schmidt","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0990","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0959-440X(02)00399-8","article-title":"Structure and mechanism of ABC transporters","volume":"1","author":"Schmitt","year":"2002","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb0995","doi-asserted-by":"crossref","first-page":"P34","DOI":"10.1016\/j.clpt.2004.12.021","article-title":"Genetic polymorphisms in the glucuronosyltransferases 1A1, 1A8 and 1A9 in relation to pharmacokinetics of furosemide","volume":"77","author":"Sehrt","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1000","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1248\/bpb.28.124","article-title":"Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes","volume":"28","author":"Shiraga","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1005","doi-asserted-by":"crossref","first-page":"8940","DOI":"10.1021\/bi060552f","article-title":"The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2","volume":"45","author":"Shukla","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cca.2007.02.014","article-title":"Enzymes and pharmacogenetics of cardiovascular drugs","volume":"381","author":"Siest","year":"2007","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1015","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00228-012-1449-5","article-title":"Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients","volume":"69","author":"Singkham","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/brain\/awf002","article-title":"Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy","volume":"125","author":"Sisodiya","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1025","first-page":"5","article-title":"The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain memorial Award lecture","volume":"51","author":"Stahelin","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1030","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1124\/jpet.104.073114","article-title":"N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7","volume":"311","author":"Staines","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1045","first-page":"172","article-title":"The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance","volume":"32","author":"Starlard-Davenport","year":"2010","journal-title":"Exp Oncol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.steroids.2007.09.007","article-title":"Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target gene","volume":"73","author":"Starlard-Davenport","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1040","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.steroids.2008.01.019","article-title":"Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues","volume":"73","author":"Starlard-Davenport","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.steroids.2006.11.016","article-title":"Phenylalanine90 and phenylalanine93 are crucial amino acids within the estrogen binding site of the human UDP-glucuronosyltransferase 1A10","volume":"72","author":"Starlard-Davenport","year":"2007","journal-title":"Steroids"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1060","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.biocel.2004.11.004","article-title":"Breast cancer resistance protein (BCRP\/ABCG2)","volume":"37","author":"Staud","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1065","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1070","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1124\/dmd.31.9.1086","article-title":"Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7","volume":"31","author":"Stone","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1075","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0016-5085(99)70239-8","article-title":"UDP-glucuronosyltransferase activity in human liver and colon","volume":"116","author":"Strassburg","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1080","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1007\/s002800051078","article-title":"Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein","volume":"42","author":"Sugiyama","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1085","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/bcr1539","article-title":"Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants","volume":"8","author":"Sun","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1090","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1124\/dmd.107.017145","article-title":"Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases","volume":"35","author":"Sun","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(06)70352-0","article-title":"Update on pharmacogenetics in epilepsy: a brief review","volume":"5","author":"Szoeke","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1105","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.addr.2010.08.006","article-title":"Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR","volume":"62","author":"Tolson","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1110","first-page":"4608","article-title":"Main drug- and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues","volume":"53","author":"Toussaint","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1115","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.trsl.2012.03.002","article-title":"Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment","volume":"160","author":"Trdan Lu\u0161in","year":"2012","journal-title":"Transl Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1120","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2125.2009.03363.x","article-title":"Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics","volume":"67","author":"Trontelj","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1125","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev.pharmtox.40.1.581","article-title":"Human UDP-glucuronosyltransferases: metabolism, expression and disease","volume":"40","author":"Tukey","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1130","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0006-3223(03)00074-X","article-title":"Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption","volume":"54","author":"Uhr","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1135","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jpsychires.2005.10.005","article-title":"Blood\u2013brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls","volume":"41","author":"Uhr","year":"2007","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1140","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuron.2007.11.017","article-title":"Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression","volume":"57","author":"Uhr","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1145","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/0091270008323258","article-title":"Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren","volume":"48","author":"Vaidyanathan","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00001813-200201000-00001","article-title":"Histone deacetylase inhibitors in cancer treatment","volume":"13","author":"Vigushin","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1155","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/00002030-200305020-00023","article-title":"Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein","volume":"17","author":"Vishnuvardhan","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1160","first-page":"5538","article-title":"Wild-type breast cancer resistance protein (BCRP\/ABCG2) is a Methotrexate Polyglutamate Transporter1","volume":"63","author":"Volk","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1170","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1124\/dmd.31.6.773","article-title":"Induction of hepatic phase II drug-metabolizing enzymes by 1,7-phenanthroline in rats is accompanied by induction of MRP3","volume":"31","author":"Wang","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1165","article-title":"Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1175","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/dmd.31.5.589","article-title":"Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1","volume":"31","author":"Watanabe","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1180","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00180192","article-title":"Pharmacokinetics of 4\u2032-epi-doxorubicin in man","volume":"1","author":"Weenen","year":"1983","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1185","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0277-5379(84)90165-2","article-title":"Metabolism of 4\u2032-modified analogs of doxorubicin. Unique glucuronidation pathway for 4\u2032-epidoxorubicin","volume":"20","author":"Weenen","year":"1984","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1190","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/bdd.699","article-title":"Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters","volume":"31","author":"Weiss","year":"2010","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1195","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1124\/dmd.106.012732","article-title":"UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics","volume":"35","author":"Wen","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1200","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/clpt.2009.12","article-title":"Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms","volume":"85","author":"Wenning","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1205","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1389200033489451","article-title":"Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and humans","volume":"4","author":"White","year":"2003","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1210","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1046\/j.1432-1327.2000.01030.x","article-title":"The relative importance of passive and P-glycoprotein mediatedanthracycline efflux from multidrug-resistant cells","volume":"267","author":"Wielinga","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1215","first-page":"19","article-title":"Integration of genetic and clinical data to analyze pharmacokinetic profile of mycophenolic acid in a population of Chinese patients with glomerular disease","volume":"3","author":"Xiang","year":"2013","journal-title":"Int Res J Pharm Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001628","article-title":"Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing","volume":"11","author":"Xu","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1225","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FPC.0b013e3283482502","article-title":"The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers","volume":"21","author":"Yamada","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1230","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2133\/dmpk.20.135","article-title":"Urinary excretion of phenytoin metabolites, 5-(4\u2032-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases","volume":"20","author":"Yamanaka","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1235","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pnpbp.2005.06.019","article-title":"Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study","volume":"30","author":"Yasui-Furukori","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1240","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.7314\/APJCP.2015.16.4.1651","article-title":"Increased UGT1A3 and UGT1A7 expression is associated with pancreatic cancer","volume":"16","author":"Yilmaz","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1245","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1158\/1078-0432.CCR-14-1370","article-title":"Molecular pathways: GLI1-induced drug glucuronidation in resistant cancer cells","volume":"21","author":"Zahreddine","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1250","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature13283","article-title":"The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation","volume":"511","author":"Zahreddine","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1255","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ejps.2005.12.007","article-title":"Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites","volume":"27","author":"Zamek-Gliszczynski","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1260","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/jnr.21898","article-title":"Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line","volume":"87","author":"Zastre","year":"2009","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1265","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1124\/dmd.106.011387","article-title":"Epirubicin glucuronidation and UGT2B7 developmental expression","volume":"34","author":"Zaya","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2016.01.009_bb1270","doi-asserted-by":"crossref","first-page":"46400","DOI":"10.1074\/jbc.M107041200","article-title":"Characterization of drug transport by the Human Multidrug Resistance Protein 3 (ABCC3)","volume":"276","author":"Zelcer","year":"2001","journal-title":"J Biol Chem"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T02:32:39Z","timestamp":1748745159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725816000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":251,"alternative-id":["S0163725816000103"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.01.009","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of glucuronidation in drug resistance","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}